Journal Mobile Options
Table of Contents
Vol. 153, No. 4, 2010
Issue release date: November 2010
Int Arch Allergy Immunol 2010;153:378–387
(DOI:10.1159/000316349)

The Induced Regulatory T Cell Level, Defined as the Proportion of IL-10+Foxp3+ Cells among CD25+CD4+ Leukocytes, Is a Potential Therapeutic Biomarker for Sublingual Immunotherapy: A Preliminary Report

Fujimura T. · Yonekura S. · Taniguchi Y. · Horiguchi S. · Saito A. · Yasueda H. · Nakayama T. · Takemori T. · Taniguchi M. · Sakaguchi M. · Okamoto Y.
aDepartment of Otolaryngology, Head and Neck Surgery, bDepartment of Immunology, Graduate School of Medicine, Chiba University, Chiba, cClinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, dDepartment of Veterinary Microbiology, School of Veterinary Medicine, Azabu University, Sagamihara, and eResearch Center for Allergy and Immunology, Yokohama Institute, RIKEN (The Institute of Physical and Chemical Research), Yokohama, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background:Japanese cedar (Cryptomeria japonica) pollinosis is one of the most prevalent allergies in Japan. Recently, two reports described the positive effects of sublingual immunotherapy (SLIT) against Japanese cedar pollinosis. However, the therapeutic biomarkers for SLIT are still unclear. We performed this unblinded, nonrandomized, open-label study to identify therapeutic biomarkers for SLIT against Japanese cedar pollinosis. Methods:We performed an open-label study during one pollinosis season in 2007, enrolling 19 patients from in-house volunteers suffering from Japanese cedar pollinosis. Peripheral blood was obtained from all participants before SLIT treatment as well as before and after the pollen season. The plasma levels of an immunoglobulin specific to a major allergen (Cry j 1) were determined. We analyzed the induction of regulatory T cells (iTregs), namely IL-10+Foxp3+ cells in CD25+CD4+ leukocytes, by flow cytometry. The Th2-type responses were analyzed by cytokine production from peripheral blood mononuclear cells after stimulation with Cry j 1. Clinical symptoms were estimated using a quality of life questionnaire in the middle of the pollen season. Results: The difference in numbers of iTregs between the medium-only control cell culture and cells stimulat- ed with Cry j 1 was significantly decreased in the non-SLIT group but was unchanged in the SLIT group after the pollen season. The subgroup of the SLIT group with increased iTregs showed more attenuated Th2-type cytokine profiles, and symptom scores in the subgroup with increased iTregs were significantly lower than those in the subgroup with decreased iTregs. Conclusion:The antigen-specific iTreg level is a potential therapeutic biomarker that correlates with clinical pollinosis symptoms and may be involved in the therapeutic mechanisms of SLIT.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Baba K, Nakae K: Epidemiology of nasal allergy through Japan in 2008 (in Japanese). Prog Med 2008;28:2001–2012.
  2. Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288–296.
  3. Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, Masuyama K, Okamoto Y, Kobayashi M: A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int 2008;57:265–275.
  4. Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunii N, Sakurai D, Fujimura T, Nakazawa K, Yasueda H: A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol 2008;146:76–84.
  5. Hirahara K, Tatsuta T, Takatori T, Ohtsuki M, Kirinaka H, Kawaguchi J, Serizawa N, Taniguchi Y, Saito S, Sakaguchi M, Inouye S, Shiraishi A: Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001;108:94–100.
  6. Pereira-Santos MC, Baptista AP, Melo A, Alves RR, Soares RS, Pedro E, Pereira-Barbosa M, Victorino RM, Sousa AE: Expansion of circulating Foxp3+CD25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008;38:291–297.
  7. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467–1472.
  8. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C: Sub- lingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707–713.
  9. Kearley J, Barker JE, Robinson DS, Lloyd CM: Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005;202:1539–1547.
  10. Practical Guideline for the Management of Allergic Rhinitis in Japan – Perennial Rhinitis and Pollinosis, 5th revision (in Japanese). Tokyo, Life Science Publishing, 2005.
  11. Okubo K, Takizawa R, Gotoh M, Okuda M: Experience of specific immunotherapy with standardized Japanese cedar pollen extract (in Japanese). Arerugi 2001;50:520–527.

    External Resources

  12. Yasueda H, Akiyama K, Maeda Y, Hayakawa T, Kaneko F, Hasegawa M, Shida T: An enzyme-linked immunosorbent assay (ELISA) for the quantitation of sugi pollen and Dermatophagoides mite allergens and its ap- plication for standardization of allergen extracts (in Japanese). Arerugi 1991;40:1218–1225.
  13. Yasueda H, Yui Y, Shimizu T, Shida T: Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria japonica) pollen. J Allergy Clin Immunol 1983;71:77–86.
  14. Yasueda H, Saito A, Sakaguchi M, Ide T, Saito S, Taniguchi Y, Akiyama K, Inouye S: Identification and characterization of a group 2 conifer pollen allergen from Chamaecyparis obtusa, a homologue of Cry j 2 from Cryptomeria japonica. Clin Exp Allergy 2000;30:546–550.
  15. Okuda M, Ohkubo K, Goto M, Okamoto H, Konno A, Baba K, Ogino S, Enomoto M, Imai T, So N, Ishikawa Y, Takenaka Y, Manndai T, Crawford B: Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. Acta Otolaryngol 2005;125:736–744.
  16. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802–809.
  17. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
  18. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, Puppo F: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95:38–44.
  19. Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:1184–1190.
  20. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ: Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106:4793–4798.
  21. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, Hafler DA: IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240–4249.
  22. Nieminen K, Valovirta E, Savolainen J: Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2009, E-pub ahead of print. DOI: 10.1111/j.1399-3038.2009.00920.x.

    External Resources

  23. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285–1294.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50